InnoCare Pharma (FRA:33C) Debt-to-Equity : 0.01 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Debt-to-Equity?

InnoCare Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €0.64 Mil. InnoCare Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €6.20 Mil. InnoCare Pharma's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €942.52 Mil. InnoCare Pharma's debt to equity for the quarter that ended in Sep. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for InnoCare Pharma's Debt-to-Equity or its related term are showing as below:

FRA:33C' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.14 Med: 0.09 Max: 0.38
Current: 0.19

During the past 7 years, the highest Debt-to-Equity Ratio of InnoCare Pharma was 0.38. The lowest was -1.14. And the median was 0.09.

FRA:33C's Debt-to-Equity is ranked worse than
55.05% of 1070 companies
in the Biotechnology industry
Industry Median: 0.145 vs FRA:33C: 0.19

InnoCare Pharma Debt-to-Equity Historical Data

The historical data trend for InnoCare Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Debt-to-Equity Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.38

0.38

0.23

0.01

0.19

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial											N/A	0.01	0.17	0.01	0.19

Competitive Comparison of InnoCare Pharma's Debt-to-Equity

For the Biotechnology subindustry, InnoCare Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InnoCare Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Debt-to-Equity falls into.

InnoCare Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

InnoCare Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	4.799)	/	1028.682
	=	0.00

InnoCare Pharma's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.642	+	6.201)	/	942.517
	=	0.01

InnoCare Pharma (FRA:33C) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

InnoCare Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines